MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.890
-0.110 (-5.50%)
At close: Apr 28, 2025, 4:00 PM
1.850
-0.040 (-2.12%)
After-hours: Apr 28, 2025, 7:27 PM EDT
Company Description
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312-416-8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial and Accounting Officer |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | 8-K | Current Report |
| Apr 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 21, 2025 | 8-K | Current Report |